Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.

[1]  Kristina Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .

[2]  P. Tucker,et al.  Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: implications for drug design. , 2000, Journal of medicinal chemistry.

[3]  H Matter,et al.  Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins. , 1999, Journal of medicinal chemistry.

[4]  M. Kurth,et al.  Carbon-carbon bond forming solid-phase reactions , 1999 .

[5]  H Matter,et al.  Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis. , 1999, Journal of medicinal chemistry.

[6]  K. Holme,et al.  Matrix metalloproteinase inhibitors: a structure-activity study. , 1998, Journal of medicinal chemistry.

[7]  R. Schleyerbach,et al.  Effects of tiaprofenic acid on urinary pyridinium crosslinks in adjuvant arthritic rats: Comparison with doxycycline , 1997, Inflammation Research.

[8]  W. Bode,et al.  1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. , 1997, European journal of biochemistry.

[9]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .

[10]  M. Maccoss,et al.  Orally active inhibitors of stromelysin-1 (MMP-3) , 1996 .

[11]  W. Hagmann,et al.  Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptides , 1996 .

[12]  W. Hagmann,et al.  Phosphinic acid inhibitors of matrix metalloproteinases , 1996 .

[13]  Gareth Jones,et al.  A genetic algorithm for flexible molecular overlay and pharmacophore elucidation , 1995, J. Comput. Aided Mol. Des..

[14]  W. Bode,et al.  Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. , 1995, Biochemistry.

[15]  J. Cook,et al.  The Pictet-Spengler condensation: a new direction for an old reaction , 1995 .

[16]  R. Huber,et al.  X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. , 1995, European journal of biochemistry.

[17]  S. Zucker,et al.  Localization of Tissue Inhibitor of Matrix Metalloproteinases in Alzheimer's Disease and Normal Brain , 1995, Journal of neuropathology and experimental neurology.

[18]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[19]  R. Huber,et al.  The X‐ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. , 1994, The EMBO journal.

[20]  M. Walid Qoronfleh,et al.  Structure of human neutrophil collagenase reveals large S1′ specificity pocket , 1994, Nature Structural Biology.

[21]  R. Huber,et al.  Structural implications for the role of the N terminus in the ‘superactivation’ of collagenases , 1994, FEBS letters.

[22]  L. Lohmander,et al.  Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. , 1993, Arthritis and rheumatism.

[23]  G. Murphy,et al.  Matrix metalloproteinases and their inhibitors. , 1992, Acta orthopaedica Scandinavica. Supplementum.

[24]  G Murphy,et al.  A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases , 1992, FEBS letters.

[25]  J. Woessner,et al.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  J. P. Thompson,et al.  Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. , 1990, The Journal of biological chemistry.

[27]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[28]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[29]  G A Petsko,et al.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.

[30]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[31]  J. Holm,et al.  Electrophilic and nucleophilic substitution in the triazole N-oxides and N-methoxytriazolium salts: preparation of substituted 1,2,3-triazoles , 1981 .

[32]  J. Powers,et al.  Design of potent reversible inhibitors for thermolysin. Peptides containing zinc coordinating ligands and their use in affinity chromatography. , 1979, Biochemistry.

[33]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[34]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[35]  G. Caldwell.  Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. , 2000, Current opinion in drug discovery & development.

[36]  Hugo Kubinyi,et al.  3D QSAR in drug design : theory, methods and applications , 2000 .

[37]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[38]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[39]  L. Matrisian,et al.  Metalloproteinases and their inhibitors in matrix remodeling. , 1990, Trends in genetics : TIG.

[40]  Matthew Clark,et al.  Comparative molecular field analysis (CoMFA). 2. Toward its use with 3D-structural databases , 1990 .

[41]  N. Borkakoti,et al.  Collagenase inhibitors: their design and potential therapeutic use. , 1987, Journal of enzyme inhibition.

[42]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[43]  Michael R. Greenberg,et al.  Chapter 1 – Theory, Methods, and Applications , 1978 .